Mitumomab Biosimilar – Anti-Ganglioside GD4 mAb – Research Grade from ProteoGenix; catalogue PX-TA1090; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Mitumomab Biosimilar, also known as Anti-Ganglioside GD4 mAb, is a monoclonal antibody that has been developed as a biosimilar to the original Mitumomab antibody. This antibody specifically targets the ganglioside GD4, which is a glycolipid expressed on the surface of various types of cancer cells. In this article, we will discuss the structure, activity, and potential applications of Mitumomab Biosimilar in research.
Mitumomab Biosimilar is a monoclonal antibody that is composed of two identical heavy chains and two identical light chains. Each of these chains is made up of amino acids that are arranged in a specific sequence. The heavy chains are approximately 50 kDa in size, while the light chains are around 25 kDa. The two chains are connected by disulfide bonds, forming a Y-shaped structure.
The variable region of Mitumomab Biosimilar, also known as the antigen-binding site, is located at the tips of the Y-shaped structure. This region is responsible for binding to the ganglioside GD4 on the surface of cancer cells. The constant region of the antibody, on the other hand, is responsible for activating immune cells and initiating an immune response against the cancer cells.
Mitumomab Biosimilar is a highly specific antibody that binds to the ganglioside GD4 with high affinity. This binding leads to the activation of immune cells, such as natural killer cells and macrophages, which then attack and destroy the cancer cells expressing GD4. This mechanism of action makes Mitumomab Biosimilar a promising therapeutic option for the treatment of various types of cancer.
cancer activity, Mitumomab Biosimilar has also been shown to have other beneficial effects. Studies have demonstrated that this antibody can induce antibody-dependent cellular cytotoxicity (ADCC), which is the process by which immune cells recognize and destroy cancer cells coated with antibodies. This further enhances the anti-tumor activity of Mitumomab Biosimilar.
As a research-grade antibody, Mitumomab Biosimilar has a wide range of potential applications in the field of cancer research. Some of the potential uses of this antibody include:
1. Studying the role of GD4 in cancer By specifically targeting and binding to the ganglioside GD4, Mitumomab Biosimilar can be used to study the role of GD4 in the development and progression of various types of cancer. This can provide valuable insights into potential therapeutic targets and aid in the development of new cancer treatments.
2. Evaluating the efficacy of other anti- cancer therapies Mitumomab Biosimilar can also be used to evaluate the efficacy of other anti- cancer therapies, such as chemotherapy and radiation therapy. By combining Mitumomab Biosimilar with these treatments, researchers can assess the synergistic effects and potentially improve the overall treatment outcome.
3. Developing new diagnostic tools The high specificity of Mitumomab Biosimilar for GD4 makes it a potential candidate for the development of diagnostic tools for cancer. By labeling the antibody with a fluorescent or radioactive marker, it can be used to detect the presence of GD4 on cancer cells, aiding in early detection and diagnosis of cancer.
4. Investigating new treatment strategies
cancer therapies, such as immunotherapy, can potentially lead to the development of new treatment strategies for cancer. This antibody can also be used to investigate the potential of GD4 as a therapeutic target for other diseases.
In summary, Mitumomab Biosimilar is a monoclonal antibody that specifically targets the ganglioside GD4 on the surface of cancer cells.
ProteoGenix catalogue number PX-TA1090. For research use only.
Target: Mitumomab Biosimilar – Anti-Ganglioside GD4 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: WB, ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Mitumomab Biosimilar – Anti-Ganglioside GD4 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
